Buy Methenolone Enanthate 100 (Primobolan) – HilmaBioCare EU
Product Overview & Pharmaceutical Specifications
Methenolone Enanthate 100 is described in the supplied product information as an injectable, oil-based sterile solution containing methenolone enanthate as its active pharmaceutical ingredient.
Product Specifications
- Product name: Methenolone Enanthate 100
- Alternative name supplied: Primobolan
- Active pharmaceutical ingredient (API): Methenolone enanthate
- Strength: 100 mg/ml
- Dosage form: Injectable, oil-based sterile solution
- Route of administration: Injection
- Pack size: 10 ml
- Packaging: Multiple-dose vial
- CAS number: 303-42-4
- Molecular formula: C27H42O3
- Molecular mass: 414.62058 g/mol
- Manufacturer/company: Hilma Biocare
- Market status supplied: Prescription
- Storage: Store in a cool, dry place between 15–25°C. Protect from light.
Pharmaceutical Formulation
The supplied product description identifies methenolone enanthate as a long-acting methenolone ester administered by intramuscular injection.
The source states that the formulation produces a rapid onset of serum methenolone followed by a continued duration of action of approximately 5–7 days after IM injection.
Methenolone is described as a dihydrotestosterone (DHT) derivative with moderately anabolic and limited androgenic properties. The supplied information states that methenolone cannot aromatize to estrogen.
Pharmacology & Product Information
Pharmacological Class
Methenolone is described in the supplied documentation as a dihydrotestosterone-derived anabolic steroid.
Anabolic steroids are synthetic derivatives of testosterone. According to the supplied clinical pharmacology information, their actions may include both anabolic and androgenic effects, and complete separation of these properties has not been achieved.
Mechanism of Action
The supplied information states that methenolone acts upon the androgen receptor and stimulates anabolic activity through increased nitrogen retention and protein synthesis in muscle tissue.
The source specifically describes methenolone as unable to aromatize to estrogen.
Endocrine Effects
The supplied clinical pharmacology information states that anabolic steroids can suppress gonadotropic pituitary function and may exert direct effects upon the testes.
During exogenous administration of anabolic androgens, endogenous testosterone release may be inhibited through suppression of pituitary luteinizing hormone (LH). At larger doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
The supplied information also identifies inhibition of gonadotropin secretion as a potential metabolic/endocrine effect.
Pharmacokinetic Information
The supplied product information states that methenolone enanthate has a continued duration of action of approximately 5–7 days after intramuscular injection.
A single-dose pharmacokinetic study cited in the supplied source reported a mean elimination half-life of approximately 6 days.
No additional pharmacokinetic parameters are supplied.
Documented Applications in Supplied Product Information
The supplied source lists Methenolone Enanthate 100 for use as alternate or adjunctive therapy for promotion of weight gain following:
- Weight loss and/or muscular atrophy associated with extensive surgery
- Chronic infections
- Long-term hospitalization
- Severe trauma
The source also lists use to compensate for protein catabolism consequent to corticosteroid therapy.
These applications are reproduced from the supplied product information and have not been independently verified against current EU clinical guidelines or marketing authorizations.
Dosage & Administration
The supplied product information states:
Adult male: 100–200 mg injected intramuscularly every 3–5 days for a duration of 8–12 weeks.
This dosage information is reproduced from the supplied source and should not be interpreted as individualized medical advice. Administration of an injectable prescription product should follow the applicable official prescribing information and the instructions of a qualified healthcare professional.
Adverse Reactions & Safety Information
The supplied product documentation reports the following adverse reactions and potential effects.
Male Reproductive Effects
- Gynecomastia
- Increased frequency of erections
- Azoospermia
- Priapism
- Oligospermia
- Prostatic hypertrophy
- Increased risk of prostate carcinoma
Skin & Appendages
- Hirsutism
- Pattern baldness
- Acne
- Gynecomastia
Fluid & Electrolyte Disturbances
- Retention of sodium
- Retention of chloride
- Retention of water
- Retention of potassium
- Retention of calcium
- Retention of inorganic phosphates
Gastrointestinal & Hepatic Effects
- Nausea
- Cholestatic jaundice
- Alterations in liver function tests
- Rarely, hepatocellular neoplasms
- Peliosis hepatis
- Hepatic adenomas
- Cholestatic hepatitis
Hematologic Effects
- Suppression of clotting factors II, V, VII and X
- Potential bleeding in patients receiving anticoagulant therapy
Nervous System Effects
- Increased or decreased libido
- Headache
- Anxiety
- Depression
- Generalized paresthesia
Metabolic Effects
- Reduced glucose tolerance
- Inhibition of gonadotropin secretion
Other Reported Effects
- Serum lipid changes
- Hypercalcaemia
- Hypertension
- Oedema
- Potentiation of sleep apnea
Contraindications
The supplied product information lists the following contraindications:
- Diagnosed or suspected carcinoma of the prostate, breast or testis
- Diagnosed or suspected female breast carcinoma with hypercalcaemia
- Pregnancy or potential pregnancy because of possible fetal masculinization
- Nephrosis
- Nephrotic phase of nephritis
- Hypercalcaemia
- Hypersensitivity to the product or any of its ingredients
- Pre-existing cardiac disease
- Pre-existing renal disease
- Pre-existing hepatic disease
The supplied source also states that treatment should be discontinued upon signs of jaundice or hepatotoxicity.
Precautions
The supplied documentation states that caution should be used when administering androgens to patients with a history of myocardial infarction or coronary artery disease because androgens may alter serum cholesterol concentrations.
Additional precautions include:
- Patients receiving oral anticoagulant therapy require close monitoring, particularly when androgen therapy is started or stopped.
- Androgens may alter the metabolism of oral hypoglycaemic agents.
- Androgens may alter insulin sensitivity in patients with diabetes mellitus.
- Adjustment of insulin or other hypoglycaemic medication may therefore be required under appropriate medical supervision.
Patient Monitoring
The supplied product information recommends monitoring of:
- Serum cholesterol
- HDL
- LDL
- Triglycerides (TG)
- Haemoglobin
- Haematocrit
- Hepatic function tests, including AST and ALT
- Prostate-specific antigen (PSA)
- Total testosterone
- Free testosterone
- Bioavailable testosterone
- Dihydrotestosterone (DHT)
- Estradiol
The source states that male patients over 40 should undergo a digital rectal examination and PSA evaluation before androgen use.
Periodic prostate evaluations should continue during androgen therapy, particularly in patients experiencing difficulty with urination or changes in voiding habits.
Drug Interactions
The supplied information identifies the following potential interactions:
Oral Hypoglycaemic Agents
The source states that methenolone may inhibit the metabolism of oral hypoglycaemic agents, potentially requiring adjustment of dosage.
Anticoagulants
Patients receiving anticoagulants should be carefully monitored during anabolic steroid therapy because anabolic steroids may increase sensitivity to oral anticoagulants.
The supplied documentation recommends regular monitoring, particularly during initiation and termination of therapy.
Presentation & Storage
Presentation: Methenolone Enanthate 100 mg/ml, 10 ml multiple-dose vial.
Storage: Store in a cool, dry place between 15–25°C. Protect from light.
Scientific & Regulatory References
No PubMed references, DOI references, clinical-literature citations, manufacturer documents or official regulatory-source links were supplied with the product data.
Accordingly, no external scientific or regulatory references have been added.
The supplied source identifies the market status as Prescription. No specific EU Member State marketing authorization, EU-wide authorization, national authorization number or regulatory approval status was supplied. Therefore, no EU-wide authorization claim is made here.
Pharmaceutical Terms & Compliance
Important: This product information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.
Methenolone Enanthate 100 is identified in the supplied source as a prescription product. Regulatory requirements, authorization status, dispensing conditions and legal availability may differ between European countries. No claim of EU-wide marketing authorization or approval is made based solely on the supplied product information.
